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Abstract
Background: Hypertrophic cardiomyopathy (HCM) is an inherited disorder with around 1400 known mutations;
however the molecular pathways leading from genotype to phenotype are not fully understood. LncRNAs, which
account for approximately 98 % of human genome, are becoming increasingly interesting with regard to various
diseases. However, changes in the expression of regulatory lncRNAs in HCM have not yet been reported.
To identify myocardial lncRNAs involved in HCM and characterize their roles in HCM pathogenesis.
Methods: Myocardial tissues were obtained from 7 HCM patients and 5 healthy individuals, and lncRNA and mRNA
expression profiles were analyzed using the Arraystar human lncRNA microarray. Real-time PCR was conducted to
validate the expression pattern of lncRNA and mRNA. Gene ontology (GO) enrichment and KEGG analysis of mRNAs
was conducted to identify the related biological modules and pathologic pathways.
Results: Approximately 1426 lncRNAs (965 up-regulated and 461 down-regulated) and 1715 mRNAs (896 up-regulated
and 819 down-regulated) were aberrantly expressed in HCM patients with fold change > 2.0. GO analysis indicated that
these lncRNAs–coexpressed mRNAs were targeted to translational process. Pathway analysis indicated that
lncRNAs–coexpressed mRNAs were mostly enriched in ribosome and oxidative phosphorylation.
Conclusion: LncRNAs are involved in the pathogenesis of HCM through the modulation of multiple
pathogenetic pathways.
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Background
Hypertrophic cardiomyopathy (HCM) represents the
most common inherited cardiac disease with an esti-
mated prevalence of 0.2 % in the general population [1,
2]. Classically, HCM is morphologically characterized by
varying degrees of myocardial hypertrophy, myocyte dis-
array and interstitial fibrosis [3, 4]. It is also a leading
cause of sudden cardiac death in young people, includ-
ing athletes [5]. Approximately 25 % of individuals with
HCM demonstrate left ventricular outflow tract (LVOT)
obstruction [6]. It has been accepted that HCM is
caused predominately by genetic variants. To date,
around 1400 mutations have been identified as being re-
sponsible for HCM pathology and more than 60 % of
genetic variants occurred in 9 sarcomeric genes, includ-
ing MYH7, MYL2 and MYBPC3 [7–10]. However, the
molecular mechanisms that underlie the pathogenesis of
HCM remain largely unknown.
Long non-coding RNAs (lncRNAs) are defined as the
transcripts of more than 200 nucleotides that structur-
ally resemble mRNAs but do not encode proteins [11].
The Encyclopedia of DNA Elements (ENCODE) project
has reported that >90 % of the genome can be tran-
scribed and the non-coding transcripts account for ap-
proximately 98 % [12]. Normally, lncRNAs are involved
in a variety of biological processes, such as cell-cycle
control, differentiation, apoptosis, chromatin remodeling
as well as epigenetic regulation [13, 14]. Dysregulation
of lncRNAs has been reported in numerous human dis-
eases, including cancer [15] and neurological diseases
[16]. However, dysregulation of lncRNAs in patients with
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HCM has never been reported. In the present study, we
hypothesized that lncRNAs were dysregulated in hyper-
trophied myocardial tissues.
In order to reveal the potential roles of lncRNAs in
the pathogenesis of HCM, we performed microarray
analysis to identify dysregulated lncRNAs and mRNAs
in HCM patients, compared to control subjects.
Methods
Ethical statement
All subjects provided written informed consent prior to
participation and all procedures in the present study
were approved by the Ethics Committee of the second
people’s hospital of Sichuan.
Tissues from patients with HCM and healthy individuals
Hypertrophied myocardial tissues used in this study
were obtained from 7 HCM patients (4 males and 3 fe-
males) with severe symptoms (New York Heart Associ-
ation functional classes III or IV) who underwent septal
myectomy at outpatient department of Chengdu first
people’s hospital (from May 2013 to December 2013).
All patients were diagnosed by two experienced clini-
cians, based on two-dimensional echocardiography dem-
onstrating an unexplained left ventricular hypertrophy
(diastolic interventricular septal thickness ≥ 15 mm and
the ratio of septal to posterior wall thickness ≥1.3) in the
absence of another cardiac or systemic disease capable
of producing a similar magnitude of hypertrophy. Be-
sides, 5 normal myocardial tissues, excised from 5
healthy individuals (3 males and 2 females) at autopsy
who voluntarily donated their body for research to the
Center of Forensic Medicine in West China, were used
as a control group. It is worth noting that we didn’t per-
form genetic scanning of 1400 known candidate genes in
patients.
The following data was collected for all subjects:
gender, age at diagnosis or death, heart rate, family his-
tory of hypertrophic cardiomyopathy, previous angina
pectoris, systolic blood pressure (SBP) and diastolic
blood pressure (DBP) (Table 1). Diseases that would
affect cardiac structures and functions were absent in
any individual. These diseases included, but not limited
to, primary hypertension with duration of more than
10 years, secondary hypertension, ischemic heart disease,
congenital heart disease, rheumatic heart disease, aortic
stenosis and other similar diseases.
RNA extraction
Myocardial specimens were quickly excised and snap-
frozen in liquid nitrogen. Tissues were homogenized in
TRIZOL reagent (Invitrogen, USA) using a Qiagen Tis-
suelyser. Total RNA was extracted in accordance with
the manufacturer’s protocol and then quantified using a
NanoDrop ND-1000 spectrophotometer (Thermo Fisher
Scientific, Waltham, MA). RNA integrity of each sample
was assessed by denaturing agarose gel electrophoresis.
RNA labeling and array hybridization
The expression of lncRNAs and mRNA was determined
using Arraystar Human LncRNA Microarray v2.0 (Capi-
talBio, China). Sample labeling and array hybridization
were performed according to the Agilent One-Color
Microarray-Based Gene Expression Analysis protocol
(Agilent Technology, USA) with minor modifications for
all 12 samples. First, rRNA was removed from total
RNA using mRNA-ONLY™ Eukaryotic mRNA Isolation
Kit (Epicentre Biotechnologies, USA). Then, each sample
was amplified and transcribed into fluorescent cRNA
along the entire length of the transcripts without 3′ bias
using the random priming method. The labeled cRNAs
were purified using an RNeasy Mini Kit (Qiagen,
Germany) and then hybridized with the specific probes
on the Human LncRNA Array v2.0. Positive probes for
housekeeping genes and negative probes are printed
onto the array for quality control. The hybridized arrays
were washed, fixed, and scanned with an Agilent DNA
Microarray Scanner G2505C.
Table 1 Clinical characteristics of HCM patients (n = 7) and controls (n = 5)
Indices HCM patients (N =7) Controls (N = 5) P-
value1 2 3 4 5 6 7 1 2 3 4 5
Gender F M M F F M M F F M M M 0.92
Age (years) 51 39 49 60 42 54 43 48 54 31 41 40 0.29
Family history of hypertrophic cardiomyopathy (Y or N) Y N N N Y Y Y N N N N N 0.04
Heart rate (bpm) 80 98 74 73 70 62 67 74 84 59 61 60 0.29
Previous angina pectoris N N Y Y Y N N N N N Y N 0.41
SBP (mmHg) 114 122 112 117 121 123 115 127 110 126 129 131 0.11
DBP (mmHg) 82 62 65 70 75 74 71 75 80 71 82 91 0.09
NYHA Classes 3 4 3 4 3 3 3 N.A. N.A. N.A. N.A. N.A.
F female, M male, Y yes, N no, SBP systolic blood pressure, DBP diastolic blood pressure, NYHA New York Heart Association, N. A. not available
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Microarray data analysis
Agilent Feature Extraction software (version 11.0.1.1)
was used to analyze acquired array images. Quantile
normalization and subsequent data processing were per-
formed using the GeneSpring GX software package (ver-
sion 11.5.1, Agilent Technologies). Differentially expressed
lncRNAs and protein-coding mRNAs between patient
group and control group were identified through Volcano
Plot filtering (fold change > 2 and P < 0.05).
Real-time PCR
Single-strand cDNA was synthesized by AMV Reverse
Transcriptase Kit (Promega, USA) in accordance with
the manufacturer’s instructions. Real-time PCR was per-
formed using SsoFast EvaGreen Supermix (Bio-Rad,
USA) on a CFX96 Real-Time PCR Detection System
(Bio-Rad, USA). The PCR conditions included an initial
step at 95 °C for 30 s, followed by 40 cycles of amplifica-
tion and quantification (95 °C for 5 s, 60 °C for 5 s).
Each DNA sample was performed in triplicates in a final
volume of 25 μl containing 1 μl of cDNA and 400 nM of
forward and reverse gene-specific primers. Relative gene
expression levels were quantified based on the cycle thresh-
old (Ct) values and ACTIN was used as an internal control.
For quantitative results, expression of each gene was repre-
sented as a fold change using the following mathematical
model: Fold change = (Etarget)
ΔCttarget (Control - Sample)/
(Eref)
ΔCtref (Control - Sample). Etarget and Eref are the PCR effi-
ciency of target gene transcript and reference gene
transcript, respectively; ΔCttarget is the Ct deviation of
control – sample of the target gene transcript; ΔCtref
is the Ct deviation of control – sample of the refer-
ence gene transcript. All primer pairs are available
upon request.
Functional group analysis
Gene Ontology (GO) analysis was performed to explore
the functions of differentially expressed coding genes
identified in this study by using the Database for Anno-
tation, Visualization and Integrated Discovery (DAVID;
http://david.abcc.ncifcrf.gov/) [17, 18]. Pathway analysis
was used to place differentially expressed coding genes
according to Kyoto Encyclopedia of Genes and Genomes
(KEGG), Biocarta and Reactome (http://www.genome.jp/
kegg/). Generally, Fisher’s exact test and v2 test were
used to classify the GO category and select the signifi-
cant pathway. Besides, the threshold of significance was
defined by the P-value and false discovery rate (FDR).
Statistical analysis
The statistical significance of microarray data was ana-
lyzed in terms of fold change using the Student’s t-test
and FDR was calculated to correct the P-value. FC ≥ 2
and P < 0.05 were used to screen the differentially
expressed lncRNAs and coding mRNAs. For other statis-
tical analysis, GraphPad Prism 5 software and Microsoft
Office software were applied. Stusent’s t-test was applied
for comparison of two groups and differences with P <
0.05 were considered statistically significant.
Results
Analysis of differentially expressed lncRNAs
In total, 8435 lncRNAs were detected by Arraystar
Human LncRNA Microarray v2.0 (Additional file 1).
From the lncRNA expression profiles, differentially
expressed lncRNAs were discriminated between patients
with HCM and controls. Hierarchical Clustering was
performed to group lncRNAs based on their expression
levels among samples (Fig. 1a). We set a threshold as
fold-change >2.0, P-value < 0.05 and FDR < 0.05, and
found that a total of 1426 lncRNAs were differentially
expressed, consisting of 965 up-regulated lncRNAs and
461 down-regulated lncRNAs. The top 10 up-regulated
and 10 down-regulated lncRNAs between two groups
were listed in Table 2.
We summarized the classification and length distribu-
tion of dysregulated lncRNAs. Among the dysregulated
lncRNAs, there were 705 intergenic, 315 antisense, 286
intronic and 120 divergent (Fig. 1b). These differentially
expressed lncRNAs showed different length on chromo-
some (DNA) ranging from 86 bp to 506 kb and 753
lncRNAs (52.8 %) were between 200 bp and 5000 bp in
length (Fig. 1c). Moreover, these differentially expressed
lncRNAs were distributed across nearly all of the human
chromosomes (Fig. 1d).
Analysis of differentially expressed mRNAs
From the analysis, we totally detected 8404 mRNAs, of
which 1715 showed significantly different expression be-
tween HCM group and control group (FC > 2.0, P-value <
0.05 and FDR < 0.05) (Additional file 2). Among them, 819
mRNAs were down-regulated and 896 mRNAs were up-
regulated. Their distinct expression patterns were presented
by hierarchical clustering analysis (Fig. 2).
Real-time PCR validation of some differentially expressed
lncRNAs and mRNAs
We randomly selected 10 dysregulated lncRNAs, includ-
ing 5 up-regulated (ENST00000453100.1, ENST00000
442794.1, ENST00000563521.1, uc.279+ and TCONS_
00013406) and 5 down-regulated (HIT000075931,
ENST00000508961.1, ENST00000504833.1, ENST0000042
0356.1 and ENST00000568819.1), for verification in these
myocardial tissues samples. A general consistency between
the real-time PCR and microarray analysis results was con-
firmed in 9 selected lncRNAs in terms of regulation direc-
tion (up-regulation or down-regulation) and significance
except ENST00000420356.1 (Fig. 3a).
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Moreover, we randomly selected 10 dysregulated
mRNAs, consisting of 5 up-regulated (TAS2R46, RFX3,
HEMGN, SSH1 and SLC1A5) and 5 down-regulated
(KLRB1, NDUFA6, ATP6V1G1, SMARCD1 and SDAD1).
All the 10 mRNAs showed the same change patterns as
shown in microarray analysis (Fig. 3b).
GO and pathway analysis for differentially expressed mRNAs
The GO categories for each gene were derived from the
GO website (www.geneontology.org) and comprised of 3
structured networks: biological processes, cellular com-
ponents and molecular function. Through GO analysis,
we found that the differentially expressed mRNAs were
principally enriched for translational elongation, transla-
tion, ribonuclearprotein complex biogenesis linked with
biological processes (Fig. 4a), and ribonucleoprotein
complex, ribosome, cytosolic ribosome involved in cellular
components (Fig. 4b), as well as structural constituent of
ribosome, structural molecule activity, RNA binding in mo-
lecular functions (Fig. 4c). Pathway analysis was carried out
Fig. 1 Overview of lncRNAs microarray analysis. a The hierarchical clustering of partial differentially expressed lncRNAs between 7 HCM patients
and 5 controls. ‘Red’ indicates high relative expression, and ‘green’ indicates low relative expression. Ctr: control. b Class distribution of
dysregulated lncRNAs, including 705 intergenic, 315 antisense, 286 intronic and 120 divergent. c The length distribution of lncRNAs on
Chromosome (DNA). The lncRNAs genes were mainly between 200 and 5000 bp in length. d Chromosomal distribution of dysregulated lncRNAs
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based on the KEGG database. The dysregulated mRNAs
were associated with 12 biological pathways, including
ribosome, oxidative phosphorylation, parkinson’s disease,
huntington’s disease, alzheimer’s disease, as well as others
(Fig. 4d).
Several lines of evidence revealed that most of
lncRNAs may act in cis and regulate gene expressions
within their chromosomal neighboring regions [19]. We
first identified the nearest protein-coding neighbor
within 100 kb of dysregulated lncRNA and then applied
GO and pathway analysis to determine the roles of these
closest coding genes. The neighbor coding gene function
of dysregulated lncRNAs mainly involved: (1) biological
process (protein metabolic process, gene expression,
mRNA metabolic process, biosynthetic process, etc.); (2)
cellular component (cytosolic ribosome, nucleus, cyto-
solic small ribosomal subunit, large ribosomal subunit,
etc.); (3) molecular function (transcription factor bind-
ing, mRNA binding, oxidoreductase activity, structural
constituent of ribosome, etc.) (Fig. 5a–c). The neighbor
gene function of dysregulated lncRNAs mainly involved
the following pathways: (1) oxidative phosphorylation;
Table 2 Top 10 up-regulated and 10 down-regulated lncRNAs between HCM patients and controls
lncRNA ID FC (abs) Regulation FDR Chrosome Strand Start1 End1 Class Database
ENST00000472913.1 8.29 up 5.11E–19 3 + 155203591 155204910 Intronic ENSEMBL
ENST00000588634.1 10.05 up 1.01E–15 19 + 11314303 11326844 Antisense ENSEMBL
TCONS_00006679 12.76 up 1.99E–10 3 - 148164072 148173245 Intergenic Human LincRNA Catalog
ENST00000440196.2 12.93 up 3.48E–21 1 - 529832 530597 Intergenic ENSEMBL
TCONS_00024565 14.61 up 1.60E–18 16 - 3995946 4002465 Intergenic Human LincRNA Catalog
ENST00000445814.1 14.90 up 1.28E–01 X - 73047635 73051045 Intergenic ENSEMBL
TCONS_00017343 15.20 up 8.42E–02 X - 73040858 73061243 Intergenic Human LincRNA Catalog
TCONS_00017432 27.97 up 6.45E–02 X + 73045949 73047819 Intergenic Human LincRNA Catalog
XR_110349.1 0.13 down 9.57E–15 12 - 49626572 49658539 Divergent RefSeq
ENST00000450016.1 0.14 down 1.92E–07 7 + 44888657 44889164 Divergent ENSEMBL
ENST00000443565.1 0.15 down 2.14E–04 1 + 81106968 81112473 Intergenic ENSEMBL
HIT000075931 0.15 down 6.17E–22 5 - 172083325 172083570 Intronic H-InvDB
TCONS_00022136 0.16 down 8.21E–09 13 + 20530916 20532202 Divergent Human LincRNA Catalog
ENST00000376482.3 0.17 down 4.56E–16 7 + 99728586 99738062 Intergenic ENSEMBL
uc.324- 0.19 down 5.29E–01 11 - 30557520 30557745 Antisense UCR
TCONS_00014990 0.19 down 2.04E–16 8 - 41998257 41998755 Intergenic Human LincRNA Catalog
TCONS_00014155 0.20 down 6.11E–14 7 + 65959182 65960476 Intergenic Human LincRNA Catalog
ENST00000563833.1 0.20 down 3.97E–09 4 - 103421997 103422476 Divergent ENSEMBL
FC fold change, FDR false discover rate
1Chromosomal positions based on GRCh38
Fig. 2 The hierarchical clustering of partial differentially expressed mRNAs. ‘Red’ indicates high relative expression, and ‘green’ indicates low
relative expression. Ctr: control
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(2) renin-angiotensin system; (3) spliceosome; (4) cardiac
muscle contraction; (5) apoptosis; (6) p53 signaling path-
way (Fig. 5d).
Discussion
In the present study, we performed a comprehensive
analysis of dysregulated lncRNAs by comparing the tran-
scriptome profiles of hypertrophied myocardial tissues
from HCM patients and normal myocardial tissues. A
total of 8435 lncRNAs and 8404 mRNAs were detected.
We identified 965 up-regulated and 461 down-regulated
lncRNAs, and summarized their general characteristics
and functional annotations. Thus, our study could pro-
vide a comprehensive understanding of lncRNAs in
HCM patients and help to elucidate the molecular
mechanisms of HCM.
To our knowledge, several proteomic and transcrip-
tome profiling of HCM have been performed and a
number of dysregulated genes have been identified be-
fore [20–23] (Additional file 3). For example, Lim et al.
identified 36 dysregulated genes involved in cytoskeletal
proteins, protein synthesis, redox system, ion channels
and those with unknown function in HCM [20]. We
compared the list of HCM-related genes between our
study and previous studies and found that some genes
appeared both in our study and previous studies, including
AFG3L2, AGPAT9, CDC14B, CMKLR1, COX4I1, GFM1,
GLUD1, LDHB, LYRM4, MRPL22, NCAM1, SLC25A46,
SS18L2, TACO1, TMEM135, TMEM41B and ZFAND1.
However, there were also many genes which occurred
only in previous studies but not in our study. We be-
lieved that discrepancy of expression profiling of mRNA
and lncRNA between our study and previous studies
was mainly derived from the following several reasons.
First, as we know, the RNA and protein profiling fluctu-
ated dramatically during different stages of diseases’ pro-
gress [24, 25]. In different progess stage of HCM, the
RNA profiling might be variable and this would be the
major reason. Second, time-dependent degradation of
nucleic acids confers great difficulty to expression ana-
lysis when postmortem tissues were used. In our study,
the normal myocardial tissues were excised from healthy
formalin-fixed postmortem individuals 3–7 days after
death, which might lead to significant RNA degradation
[26, 27]. Inhomogenous RNA degradation would result
in the change of relative expression of RNAs, Third,
Fig. 3 Real-time PCR validation of some differentially expressed lncRNAs and mRNA from microarray data. a 10 lncRNAs were randomly chosen
for real-time PCR validation. b 10 mRNAs were randomly chosen for real-time PCR validation. Fold changes were calculated by the 2-△△Ct method.
Data shown are representative of 7 patients and 5 controls; error bars represent means ± SEM, ★P < 0.05, ★★P < 0.01, ★★★P < 0.001, N.S. not sig-
nificant (student t test). Apart from ENST00000420356.1, the real-time PCR validation results of all lncRNAs and mRNAs were generally consistent
with microarray data
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Fig. 4 Enrichment analysis of pathways and GO terms for differentially expressed mRNAs. a-c GO analysis according to biological process, cellular
component and molecular function, respectively. d Pathway analysis based on the KEGG database. P-values < 0.05 using the two-sided Fisher’s
exact test was defined to be statistically significant
Fig. 5 Enrichment analysis of pathways and GO terms for protein-coding neighbors of dysregulated lncRNAs. a-c GO analysis according to bio-
logical process, cellular component and molecular function, respectively. d Pathway analysis based on the KEGG database. P-values < 0.05 using
the two-sided Fisher’s exact test was defined to be statistically significant
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different detection platforms may have huge impact on
the profiling result and this is why subsequent experi-
mental verification is essential. Most of the previous
studies used Affymetrix platform for profiling analysis,
while, in our study, Arraystar Human LncRNA Micro-
array v2.0 was used. The molecular mechanisms respon-
sible for HCM have been extensively explored. However
the pathogenesis of this disease is still largely unknown.
Most of the genes discovered in HCM were protein-
coding while non-coding genes were scarcely reported.
Technological improvements have contributed to reveal
the importance of lncRNA underling various diseases
[28]. Up till now, both transcriptome sequencing [29]
and microarrays [30] have been applied to identify differ-
ential lncRNA expression. To the best of our knowledge,
only one lncRNA, Myheart, was reported to be involved
in cardiac hypertrophy in previous studies. Myheart
could protect heart from pathological hypertrophy by its
interaction with chromatin [31, 32]. Our study could
greatly enrich the lncRNAs spectrums involved in the
pathogenesis of HCM.
The Gene Ontology project provides a controlled vo-
cabulary to describe gene attributes unbiasedly [18]. Inter-
estingly, in our study, these dysregulated genes were
mainly involved in translational regulation, including
translational elongation, ribonucleoprotein complex, ribo-
some and structural constituent of ribosome. As we know,
once the translational process was disrupted, the levels of
numerous proteins would be influenced, which might
have profound effects on normal physiological processes
[33, 34]. However, no previous study of HCM was concen-
trated on translational regulation and we hold the opinion
that it would be quite meaningful to investigate transla-
tional dysregulation in HCM. Pathway analysis identified
7 distinct pathways, including ribosome and oxidative
phosphorylation. `It has been reported that CREB contrib-
utes to physiological hypertrophy by enhancing expression
of genes in complex I of oxidative phosphorylation [35].
Many more studies are needed to fully understand the
molecular mechanisms of HCM in the future.
Conclusion
LncRNAs are involved in the pathogenesis of HCM
through the modulation of multiple pathogenetic path-
ways. Our study could also provide clinic evidence for
the diagnosis and prognostic management of HCM pa-
tients, as well as medical intervening for HCM.
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